DONG-A ST CO.,LTD
Financials
Valuation Metrics
DONG-A ST CO.,LTD's Market Cap is ₩3414B. At end of 2025 it was ₩4871B. Ranked #573 of 2,405 in KR market (top 24%), #343 of 778 on KOSPI (top 44%), #59 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 26%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 341.45B KRW | KR#573/2,405 Sec#59/231 |
| Revenue | 860.94B KRW | KR#445/2,405 Sec#18/231 |
| Net Income | 5.83B KRW | KR#1,150/2,405 Sec#73/231 |
| Total Assets | 1.35T KRW | KR#398/2,405 Sec#18/231 |
| Net Assets | 674.03B KRW | KR#399/2,405 Sec#26/231 |
| Employees | 1,695 | KR#164/2,405 Sec#9/231 |
| Value | ||
| P/E | 58.61x | KR#1,445/2,405 Sec#95/231 |
| P/B | 0.51x | KR#885/2,405 Sec#43/231 |
| P/S | 0.40x | KR#818/2,405 Sec#32/231 |
| EV/EBITDA | 27.08x | KR#1,169/2,405 Sec#70/231 |
| FCF Yield | 1.65% | KR#1,091/2,405 Sec#74/231 |
| Profitability | ||
| ROE | 0.86% | KR#1,486/2,405 Sec#104/231 |
| ROA | 0.43% | KR#1,488/2,405 Sec#104/231 |
| Op. Margin | 2.94% | KR#1,256/2,405 Sec#90/231 |
| Revenue Growth | 15.38% | KR#668/2,405 Sec#63/231 |
| Financial Health | ||
| Debt Ratio | 100.97% | KR#1,558/2,405 Sec#179/231 |
| Total Debt | 479.96B KRW | KR#311/2,405 Sec#10/231 |
| FCF | 5.64B KRW | KR#872/2,405 Sec#58/231 |
| Cash | 136.12B KRW | KR#370/2,405 Sec#16/231 |
| Current Ratio | 1.36x | KR#1,304/2,405 Sec#137/231 |
| Net Debt/EBITDA | 13.59x | KR#1,305/2,405 Sec#92/231 |
| Dividend | ||
| Div. Yield | 1.91% | KR#940/2,405 Sec#49/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | -24.74% | KR#1,322/2,405 Sec#97/231 |
| 1M Return | 0.43% | KR#305/2,405 Sec#32/231 |
| From 52W High | -37.83% | KR#683/2,405 Sec#44/231 |
| 1Y MDD | -41.95% | KR#637/2,405 Sec#43/231 |
| Trading | ||
| Volume | 10,562 shares | KR#1,815/2,405 Sec#178/231 |
| Trading Value | 365.1M KRW | KR#911/2,405 Sec#101/231 |
| Foreign Own. | 19.22% | KR#240/2,405 Sec#12/231 |
| Per Share | ||
| EPS | 599 KRW | KR#931/2,405 Sec#65/231 |
| BPS | 69,288 KRW | KR#195/2,405 Sec#13/231 |
Company Info
Dong-A ST was established in 2013 as a spin-off from Dong-A Socio Holdings and acquired a global ADC specialist in 2023 to secure technology and pipelines. The company manufactures and sells developed new drugs such as STILLEN, Zydena, and Motilitone, along with specialized pharmaceuticals like Growtropin and Gaster, produced at its Cheonan, Daegu, and Songdo campuses. Dong-A ST is expanding R&D investment to develop new drugs for metabolic diseases including diabetes, obesity, and MASH, thereby strengthening its market dominance with a diverse portfolio. Dong-A ST is headquartered in Dongdaemun-gu, Seoul.